PE20242204A1 - Compuestos de carbolina y uso de los mismos - Google Patents
Compuestos de carbolina y uso de los mismosInfo
- Publication number
- PE20242204A1 PE20242204A1 PE2024001503A PE2024001503A PE20242204A1 PE 20242204 A1 PE20242204 A1 PE 20242204A1 PE 2024001503 A PE2024001503 A PE 2024001503A PE 2024001503 A PE2024001503 A PE 2024001503A PE 20242204 A1 PE20242204 A1 PE 20242204A1
- Authority
- PE
- Peru
- Prior art keywords
- deuterium
- fluoro
- hydroxy
- halo
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere a compuestos de carbolina, de formula I, o una forma del mismo, en donde: R1 es H, deuterio, amino, nitro o fluoro; R2 es halo, alquilo C1-4, alquenilo C2-4, nitro, alcoxi C1-4, entre otros; R3 es H, deuterio, amino o fluoro; R4 es H, amino o hidroxi; Q1 es CR5 o N; Q2 es CR6 o N; en donde Q1 y Q2 no son simultaneamente N; R5 y R7 se seleccionan independientemente entre H, deuterio, halo, ciano, alquilo C1-4, entre otros; Q3 es CR8 o N; R8 es H o deuterio; R9 es H, deuterio, halo, ciano, hidroxi, entre otros; Q4 es CR10 o N; R10 es H, deuterio, fluoro o hidroxi; R11 es H, deuterio, fluoro o hidroxi. Un compuesto seleccionado es 6-cloro-2-(5-cloropirimidin-2-il)-1-(4-fluorofenil)-2,3,4,9-tetrahidro-1Hpirido[3,4-b]indol. Estos compuestos inhiben la dihidroorotato deshidrogenasa (DHODH). Tambien se refiere a la preparacion de dichos compuestos, una composicion farmaceutica que lo comprende, y su uso para tratar una enfermedad o trastorno susceptible de inhibicion de la DHODH.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163295844P | 2021-12-31 | 2021-12-31 | |
| PCT/US2022/082622 WO2023130070A2 (en) | 2021-12-31 | 2022-12-30 | Carboline compounds and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20242204A1 true PE20242204A1 (es) | 2024-11-19 |
Family
ID=87000358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001503A PE20242204A1 (es) | 2021-12-31 | 2022-12-30 | Compuestos de carbolina y uso de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250186437A1 (es) |
| EP (1) | EP4416148A4 (es) |
| JP (1) | JP2025501285A (es) |
| KR (1) | KR20240144093A (es) |
| CN (1) | CN118613481A (es) |
| AU (1) | AU2022425632A1 (es) |
| CA (1) | CA3237691A1 (es) |
| CL (1) | CL2024001990A1 (es) |
| CO (1) | CO2024008550A2 (es) |
| CR (1) | CR20240264A (es) |
| IL (1) | IL313144A (es) |
| MX (1) | MX2024008030A (es) |
| PE (1) | PE20242204A1 (es) |
| WO (1) | WO2023130070A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024308389A1 (en) * | 2023-06-26 | 2026-01-29 | Ptc Therapeutics, Inc. | Carboline compounds and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855295B2 (en) * | 2004-01-23 | 2010-12-21 | Novartis Vaccines And Diagnostics, Inc. | Tetrahydrocarboline compounds as anticancer agents |
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| US8076353B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
| EP1737461B1 (en) | 2004-03-15 | 2012-12-12 | PTC Therapeutics, Inc. | Carboline derivatives useful in the inhibition of angiogenesis |
| WO2007002051A1 (en) * | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
| US7863274B2 (en) * | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
| CA3184380A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| CA2763479A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Processes for the preparation of substituted tetrahydro beta-carbolines |
| US20130171103A1 (en) * | 2010-05-27 | 2013-07-04 | Ptc Therapeutics, Inc. | Methods for treating viral conditions |
| WO2019028171A1 (en) | 2017-08-01 | 2019-02-07 | Ptc Therapeutics, Inc. | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS |
| BR112021001859A2 (pt) | 2018-08-03 | 2021-04-27 | Ptc Therapeutics, Inc. | formas de dosagem oral biodisponíveis |
| WO2021226478A1 (en) * | 2020-05-08 | 2021-11-11 | Ptc Therapeutics, Inc. | Dhodh inhibitor for the treatment of covid-19 |
-
2022
- 2022-12-30 CA CA3237691A patent/CA3237691A1/en active Pending
- 2022-12-30 MX MX2024008030A patent/MX2024008030A/es unknown
- 2022-12-30 WO PCT/US2022/082622 patent/WO2023130070A2/en not_active Ceased
- 2022-12-30 CN CN202280087038.XA patent/CN118613481A/zh active Pending
- 2022-12-30 JP JP2024539799A patent/JP2025501285A/ja active Pending
- 2022-12-30 EP EP22917604.5A patent/EP4416148A4/en active Pending
- 2022-12-30 IL IL313144A patent/IL313144A/en unknown
- 2022-12-30 PE PE2024001503A patent/PE20242204A1/es unknown
- 2022-12-30 KR KR1020247015685A patent/KR20240144093A/ko active Pending
- 2022-12-30 AU AU2022425632A patent/AU2022425632A1/en active Pending
- 2022-12-30 CR CR20240264A patent/CR20240264A/es unknown
- 2022-12-30 US US18/725,509 patent/US20250186437A1/en active Pending
-
2024
- 2024-06-27 CL CL2024001990A patent/CL2024001990A1/es unknown
- 2024-06-28 CO CONC2024/0008550A patent/CO2024008550A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL313144A (en) | 2024-07-01 |
| CA3237691A1 (en) | 2023-07-06 |
| CO2024008550A2 (es) | 2024-08-08 |
| JP2025501285A (ja) | 2025-01-17 |
| US20250186437A1 (en) | 2025-06-12 |
| CN118613481A (zh) | 2024-09-06 |
| KR20240144093A (ko) | 2024-10-02 |
| MX2024008030A (es) | 2024-07-12 |
| WO2023130070A2 (en) | 2023-07-06 |
| CL2024001990A1 (es) | 2024-11-04 |
| EP4416148A4 (en) | 2025-10-29 |
| EP4416148A2 (en) | 2024-08-21 |
| WO2023130070A3 (en) | 2023-08-03 |
| AU2022425632A1 (en) | 2024-05-30 |
| CR20240264A (es) | 2024-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| AR068846A1 (es) | Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer | |
| AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
| PE20060285A1 (es) | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) | |
| UY28578A1 (es) | Derivados de amida | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| NI200700270A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| PE20081393A1 (es) | Derivados de quinolina como inhibidores de csf-1r | |
| AR066509A1 (es) | Derivados de tiazol, medicamentos que los contienen, proceso de preparacion y usos como moduladores de beta amiloide. | |
| PE20170247A1 (es) | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1 | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| PE20040937A1 (es) | Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4) | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| PE20070181A1 (es) | DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA | |
| AR072578A1 (es) | Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| CL2012000516A1 (es) | Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros. | |
| AR062405A1 (es) | Derivados de isoindol | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa |